Figure 6From: A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors Waterfall plot of RAS signature score in patients who experienced disease control (blue) or progressive disease (red) after Cetuximab therapy. The Y-axis shows RAS signature score relative to the mean of all tumors in this dataset. Fisher's exact test p-value for the difference between the disease control and progressive disease groups is shown. Data is derived from [5], and includes all patients with known response.Back to article page